International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

International System for Human Cytogenetic Nomenclature

National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619

Myelodysplastic syndromes: a scoring system with prognostic significance

Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406

The 5q− anomaly

BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase

Zhou, L., McMahon, C. M., Bhagat, T. D., Alencar, C., Yu, Y., Fazzari, M. J., Sohal, D. P. S., Heuck, C. J., Gundabolu, K., Ng, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2933 · Cited by 138

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

Mahfouz, R. Z., Jankowska, A., Ebrahem, Q., Gu, X., Visconte, V., Tabarroki, A., Terse, P., Covey, J. M., Chan, K. K., Ling, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1722 · Cited by 136

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Stahl, M. F., DeVeaux, M., de Witte, T., Neukirchen, J., Sekeres, M. A., Brunner, A. M., Roboz, G. J., Steensma, D. P., Bhatt, V. R., Platzbecker, U., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019414 · Cited by 138

Incidence and Burden of the Myelodysplastic Syndromes

Cogle, C. R. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0269-y · Cited by 141

Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Beran, M., Estey, E. H., O'Brien, S. M., Cortes, J. E., Koller, C. A., Giles, F. J., Kornblau, S. M., Andreeff, M., Vey, N., Pierce, S. R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2819 · Cited by 136

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004) · Blood · doi:10.1182/blood-2004-02-0754 · Cited by 135

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

Porta, M. G. D., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.55 · Cited by 139

Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes

Malcovati, L. (2007) · Leukemia Research · doi:10.1016/s0145-2126(07)70459-9 · Cited by 135

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Gore, S. D., Fenaux, P., Santini, V., Bennett, J. M., Silverman, L. R., Seymour, J. F., Hellström‐Lindberg, E., Swern, A. S., Beach, C. L., & List, A. F. (2013) · Haematologica · doi:10.3324/haematol.2012.074831 · Cited by 135

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

Voso, M. T., Fenu, S., Latagliata, R., Buccisano, F., Piciocchi, A., Spiriti, M. A. A., Breccia, M., Criscuolo, M., Andriani, A., Mancini, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.0764 · Cited by 135

Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)

Germing, U., Kündgen, A., & Gattermann, N. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819042000207271 · Cited by 135

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Raffoux, E., Cras, A., Recher, C., Boëlle, P.-Y., de Labarthe, A., Turlure, P., Marolleau, J.-P., Reman, O., Gardin, C., Victor, M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.106 · Cited by 134

Whole genome scanning as a cytogenetic tool in hematologic malignancies

Maciejewski, J. P., & Mufti, G. J. (2008) · Blood · doi:10.1182/blood-2008-02-130435 · Cited by 133

Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

Messa, E., Carturan, S., Maffè, C., Pautasso, M., Bracco, E., Roetto, A., Messa, F., Arruga, F., Defilippi, I., Rosso, V., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016824 · Cited by 140

Loss of chromosome Y (LOY) in blood cells is associated with increased risk for disease and mortality in aging men

Forsberg, L. A. (2017) · Human Genetics · doi:10.1007/s00439-017-1799-2 · Cited by 134

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*

Santini, V., Fenaux, P., Mufti, G. J., Hellström‐Lindberg, E., Silverman, L. R., List, A. F., Gore, S. D., Seymour, J. F., Backstrom, J. T., & Beach, C. L. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01456.x · Cited by 133

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes

Garcia‐Manero, G., & Fenaux, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0854 · Cited by 136

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Khan, S. N., Jankowska, A. M., Mahfouz, R. Z., Dunbar, A. J., Sugimoto, Y., Hosono, N., Hu, Z., Cheriyath, V., Vatolin, S., Przychodzen, B. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.80 · Cited by 139

Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study

Giannouli, S. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh136 · Cited by 132

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies

Giagounidis, A. A. N., Germing, U., & Aul, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1437 · Cited by 136

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Sekeres, M. A., Tiu, R. V., Komrokji, R. S., Lancet, J. E., Advani, A. S., Afable, M. G., Englehaupt, R. K., Juersivich, J., Cuthbertson, D. D., Paleveda, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-434639 · Cited by 131

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities

Eissa, H., Gooley, T. A., Sorror, M. L., Nguyen, F., Scott, B. L., Doney, K., Loeb, K. R., Martin, P. J., Pagel, J. M., Radich, J. P., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.09.018 · Cited by 130

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Platzbecker, U., Symeonidis, A. S., Olíva, E. N., Goede, J. S., Delforge, M., Mayer, J., Slama, B., Badre, S., Gasal, E., Mehta, B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.192 · Cited by 130

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors

Tehranchi, R., Fadeel, B., Forsblom, A., Christensson, B., Samuelsson, J., Zhivotovsky, B., & Hellström‐Lindberg, E. (2003) · Blood · doi:10.1182/blood-2002-06-1774 · Cited by 130

Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome

Epling‐Burnette, P. K., Painter, J. S., Rollison, D. E. M., Ku, E., Vendron, D., Widen, R. H., Boulware, D. C., Zou, J., Bai, F., & List, A. F. (2007) · Leukemia · doi:10.1038/sj.leu.2404590 · Cited by 130

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

Field, T. L., Perkins, J. B., Huang, Y., Kharfan‐Dabaja, M. A., Alsina, M., Ayala, E., Fernandez, H. F., Janssen, W. E., Lancet, J. E., Perez, L. E., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.134 · Cited by 129

Myelodysplastic syndrome is not merely “preleukemia”

Albitar, M. X., Manshouri, T., Shen, Y., Liu, D., Beran, M., Kantarjian, H. M., Rogers, A. M., Jilani, I. B., Lin, C., Pierce, S. A., et al. (2002) · Blood · doi:10.1182/blood.v100.3.791 · Cited by 129

Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology

_, _. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0007 · Cited by 128

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Fu, B., Tang, G., Goswami, M., Singh, R. R., Kanagal‐Shamanna, R., Pierce, S. A., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.006 · Cited by 125

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

Aribi, A. M., Borthakur, G. M., Ravandi, F., Shan, J., Davisson, J., Cortes, J. E., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22457 · Cited by 128

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

Navas, T. A., Mohindru, M., Estes, M. L., Jing, Y., Sokol, L., Pahanish, P., Parmar, S., Haghnazari, E., Zhou, L., Collins, R. H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-023093 · Cited by 128

Myelodysplastic syndromes: 2014 update on diagnosis, risk‐stratification, and management

Garcia‐Manero, G. (2014) · American Journal of Hematology · doi:10.1002/ajh.23642 · Cited by 127

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

Wijermans, P., Rüter, B. H., Baer, M. R., Slack, J. L., Saba, H. I., & Lübbert, M. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.004 · Cited by 129

Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older

Wallen, H. D., Gooley, T. A., Deeg, H. J., Pagel, J. M., Press, O. W., Appelbaum, F. R., Storb, R. F., & Gopal, A. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.694 · Cited by 127

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

Kiladjian, J., Bourgeois, E., Lobe, I., Braun, T., Visentin, G., Bourhis, J.-H., Fenaux, P., Chouaı̈b, S., & Caignard, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404080 · Cited by 126

The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors

Matarraz, S., López, A., Bárrena, S., Fernandez, C., Jensen, E., Flores-Montero, J. A., Bárcena, P., Rasillo, A., Sayagués, J. M., Sánchez, M. L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.49 · Cited by 126

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

Platzbecker, U., Bornhäuser, M., Germing, U., Stumpf, J., Scott, B. L., Kröger, N. M., Schwerdtfeger, R., Böhm, A., Kobbe, G., Theuser, C., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.08.006 · Cited by 126

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

Sarhan, D., Brandt, L., Felices, M., Guldevall, K., Lenvik, T. R., Hinderlie, P., Curtsinger, J., Warlick, E. D., Spellman, S. R., Blazar, B. R., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017012369 · Cited by 125

Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome

Malcovati, L., Porta, M. G. D., Lunghi, M., Pascutto, C., Vanelli, L., Travaglino, E., Maffioli, M., BERNASCONI, P. P., Lazzarino, M., Invernizzi, R., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403680 · Cited by 125

Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome

Deeg, H. J., Beckham, C., Loken, M. R., Bryant, E. M., Lesnikova, M. P., Shulman, H. M., & Gooley, T. A. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009089441 · Cited by 125

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

Kurzrock, R., Kantarjian, H. M., Cortes, J. E., Singhania, N., Thomas, D. A., Wilson, E. F., Wright, J. J., Freireich, E. J., Talpaz, M., & Sebti, S. M. (2003) · Blood · doi:10.1182/blood-2002-11-3359 · Cited by 125

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Germing, U., Lauseker, M., Hildebrandt, B., Symeonidis, A. S., Čermák, J., Fenaux, P., Kelaïdi, C., Pfeilstöcker, M., Nösslinger, T., Sekeres, M. A., et al. (2012) · Leukemia · doi:10.1038/leu.2011.391 · Cited by 126

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis

Jerez, A., Sugimoto, Y., Makishima, H., Verma, A. K., Jankowska, A. M., Przychodzen, B. P., Visconte, V., Tiu, R. V., O’Keefe, C. L., Mohamedali, A. M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-397620 · Cited by 127

Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes

Buesche, G., Teoman, H., Wilczak, W., Ganser, A., Hecker, H., Wilkens, L., Göhring, G., Schlegelberger, B., Bock, O., Georgii, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405030 · Cited by 122

Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia

Yamazaki, J., Taby, R. F., Vasanthakumar, A., Macrae, T. A., Ostler, K. R., Shen, L., Kantarjian, H. M., Estecio, M. R., Jelı́nek, J., Godley, L. A., et al. (2012) · Epigenetics · doi:10.4161/epi.7.2.19015 · Cited by 125

Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries

Chen, B., Zhao, W.-L., Jin, J., Xue, Y.-Q., Cheng, X., Xt, C., Cui, J., Chen, Z.-M., Cao, Q., Yang, G., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403688 · Cited by 122

Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis

Zang, D. Y., Goodwin, R. G., Loken, M. R., Bryant, E. M., & Deeg, H. J. (2001) · Blood · doi:10.1182/blood.v98.10.3058 · Cited by 122

Myelodysplastic Syndromes

List, A. F., Vardiman, J. W., Issa, J. J., & deWitte, T. (2004) · Hematology · doi:10.1182/asheducation-2004.1.297 · Cited by 120

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Toma, A., Kosmider, O., Chevret, S., Delaunay, J., Stamatoullas, A., Rosé, C., Beyne‐Rauzy, O., Baños, A., Guerci‐Bresler, A., Wickenhauser, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.296 · Cited by 126

International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis

Hussein, K., Pardanani, A. D., Dyke, D. L. V., Hanson, C. A., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-08-240135 · Cited by 121

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

Mallo, M., Cervera, J., Schanz, J., Such, E., Garcia‐Manero, G., Luño, E., Steidl, C., Espinet, B., Vallespı́, T., Germing, U., et al. (2010) · Leukemia · doi:10.1038/leu.2010.231 · Cited by 121

Stem and progenitor cell alterations in myelodysplastic syndromes

Shastri, A., Will, B., Steidl, U. G., & Verma, A. K. (2017) · Blood · doi:10.1182/blood-2016-10-696062 · Cited by 123

Infections in myelodysplastic syndromes

Toma, A., Fenaux, P., Dreyfus, F., & Cordonnier, C. (2012) · Haematologica · doi:10.3324/haematol.2012.063420 · Cited by 121

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial

Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0916 · Cited by 120

Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution

Nösslinger, T., Reisner, R., Koller, E., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E., & Pfeilstöcker, M. (2001) · Blood · doi:10.1182/blood.v98.10.2935 · Cited by 119

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

Komrokji, R. S., Garcia‐Manero, G., Adès, L., Prébet, T., Steensma, D. P., Jurcic, J. G., Sekeres, M. A., Berdeja, J. G., Savona, M. R., Beyne‐Rauzy, O., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30002-4 · Cited by 122

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Itzykson, R., Fenaux, P., Bowen, D., Cross, N. C. P., Cortes, J. E., de Witte, T., Germing, U., Onida, F., Padron, E., Platzbecker, U., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000150 · Cited by 118

Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

Nakai, K., Kanda, Y., Fukuhara, S., Sakamaki, H., Okamoto, S., Kodera, Y., Tanosaki, R., Takahashi, S., Matsushima, T., Atsuta, Y., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403640 · Cited by 118

Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome

Kerbauy, D. M. B., & Deeg, H. J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.09.007 · Cited by 119

‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins

Parker, Fishlock, Mijovic, Czepulkowski, Pagliuca, A., & Mufti (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01114.x · Cited by 118

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

Seymour, J. F., Fenaux, P., Silverman, L. R., Mufti, G. J., Hellström‐Lindberg, E., Santini, V., List, A. F., Gore, S. D., Backstrom, J. T., McKenzie, D., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.005 · Cited by 117

Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan

Oran, B., Giralt, S., Saliba, R. M., Hosing, C. M., Popat, U., Khouri, I. F., Couriel, D. R., Qazilbash, M. H., Anderlini, P. N., Kebriaei, P., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.11.024 · Cited by 117

Myelodysplastic Syndromes

Greenberg, P. L., Young, N. S., & Gattermann, N. (2002) · Hematology · doi:10.1182/asheducation-2002.1.136 · Cited by 117

Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine

Lee, J., Joo, Y., Kim, H., Ryoo, H. M., Kim, M. K., Lee, G., Lee, J., Lee, W. S., Park, J.-H., Bae, S.-H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2362 · Cited by 116

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Santini, V., Alessandrino, P. E., Angelucci, E., Barosi, G., Billio, A., Maïo, M. D., Finelli, C., Locatelli, F., Marchetti, M., Morra, E., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.018 · Cited by 114

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group

Sperr, W. R., Wimazal, F., Kundi, M., Baumgärtner, C., Nösslinger, T., Makrai, A., Stauder, R., Krieger, O., Pfeilstöcker, M., & Valent, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp258 · Cited by 116

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

Gattermann, N. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0118-z · Cited by 116

Immunophenotypic clustering of myelodysplastic syndromes

Maynadié, M. (2002) · Blood · doi:10.1182/blood-2002-01-0230 · Cited by 116

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment

Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00112-x · Cited by 117

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome

Scott, B. L., Storer, B. E., Loken, M. R., Storb, R. F., Appelbaum, F. R., & Deeg, H. J. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.10.001 · Cited by 115

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

Kantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

Follo, M. Y., Finelli, C., Mongiorgi, S., Clissa, C., Bosi, C., Testoni, N., Chiarini, F., Ramazzotti, G., Baccarani, M., Martelli, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907109106 · Cited by 114

Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes

Garcia‐Manero, G., Jabbour, E. J., Borthakur, G. M., Faderl, S. H., Estrov, Z. E., Yang, H., Maddipoti, S., Godley, L. A., Gabrail, N. Y., Berdeja, J. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6823 · Cited by 114

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

Garcia‐Manero, G., Gore, S. D., Kambhampati, S., Scott, B. L., Tefferi, A., Cogle, C. R., Edenfield, W. J., Hetzer, J., Kumar, K., Laille, E. J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.265 · Cited by 114

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Bravo, G. M., Kanagal‐Shamanna, R., Sasaki, K., Patel, K. P., Gañán‐Gómez, I., Jabbour, E. J., Kadia, T. M., Ravandi, F., Dinardo, C. D., Borthakur, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026989 · Cited by 113

Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes

List, A. F., Beran, M., DiPersio, J. F., Slack, J. L., Vey, N., Rosenfeld, C. S., & Greenberg, P. L. (2003) · Leukemia · doi:10.1038/sj.leu.2403021 · Cited by 114

Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes

Fenaux, P. (2001) · International Journal of Hematology · doi:10.1007/bf02994004 · Cited by 114

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

Cortes, J. E., Smith, B. D., Wang, E. S., Merchant, A. A., Oehler, V. G., Arellano, M. L., DeAngelo, D. J., Pollyea, D. A., Sekeres, M. A., Robak, T., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25238 · Cited by 113

New Lesions Detected by Single Nucleotide Polymorphism Array–Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia

Tiu, R. V., Gondek, L. P., O’Keefe, C. L., Huh, J., Sekeres, M. A., Elson, P. J., McDevitt, M. A., Wang, X., Levis, M. J., Karp, J. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9840 · Cited by 112

How I treat chronic myelomonocytic leukemia

Solary, É., & Itzykson, R. (2017) · Blood · doi:10.1182/blood-2017-04-736421 · Cited by 112

Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway

Zheng, Q., Zhao, Y., Guo, J., Zhao, S., Fei, C., Xiao, C. W., Wu, D., Wu, L., Li, X., & Chang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0552-7 · Cited by 116

Myelodysplastic syndromes: moving towards personalized management

Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 109

Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes

Pozdnyakova, O., Miron, P. M., Tang, G., Walter, O., Raza, A., Woda, B. A., & Wang, S. A. (2008) · Cancer · doi:10.1002/cncr.23977 · Cited by 112

Cytogenetics in Myelodysplastic Syndromes

Ohyashiki, K., Kodama, A., & Ohyashiki, J. H. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-074-4_6 · Cited by 112

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

Jabbour, E. J., Garcia‐Manero, G., Strati, P., Mishra, A., Ali, N. H. A., Padron, E., Lancet, J. E., Kadia, T. M., Daver, N. G., O'Brien, S. M., et al. (2014) · Cancer · doi:10.1002/cncr.29145 · Cited by 111

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

Teachey, D. T., Grupp, S. A., & Brown, V. I. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07657.x · Cited by 114

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

Scott, B. L., Wells, D. A., Loken, M. R., Myerson, D., Leisenring, W. M., & Deeg, H. J. (2008) · Blood · doi:10.1182/blood-2008-05-153700 · Cited by 111

Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications

Calvo, K. R., Vinh, D. C., Maric, I., Wang, W., Noël, P., Stetler-Stevenson, M. A., Arthur, D., Raffeld, M. A., Dutra, A., Pak, E. D., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.041152 · Cited by 111

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS

Valent, P., Bain, B. J., Bennett, J. M., Wimazal, F., Sperr, W. R., Mufti, G. J., & Horny, H. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.08.016 · Cited by 111

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

Sekeres, M. A., List, A. F., Cuthbertson, D. D., PAQUETTE, R. L., Ganetsky, R., Latham, D., Paulic, K., Afable, M. G., Saba, H. I., Loughran, T. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0745 · Cited by 109

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

Ossenkoppele, G. J. (2003) · Blood · doi:10.1182/blood-2003-07-2195 · Cited by 110

Acquired α-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies

Steensma, D. P., Gibbons, R. J., & Higgs, D. R. (2004) · Blood · doi:10.1182/blood-2004-07-2792 · Cited by 113

Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management

Garcia‐Manero, G. (2015) · American Journal of Hematology · doi:10.1002/ajh.24102 · Cited by 112

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

Gurion, R., Vidal, L., Gafter-Gvili, A., Belnik, Y., Yeshurun, M., Raanani, P., & Shpilberg, O. (2009) · Haematologica · doi:10.3324/haematol.2009.010611 · Cited by 109

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern, W., Haferlach, C., Schnittger, S., & Haferlach, T. (2010) · Cancer · doi:10.1002/cncr.25353 · Cited by 109

Myelodysplastic Syndrome

Hofmann, W., & Koeffler, H. P. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104704 · Cited by 109

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry

Bernal, T., Martínez‐Camblor, P., Sánchez‐García, J., de Paz, R., Luño, E., Nomdedeu, B., Ardanaz, M., Pedro, C., Amigo, M. L., Xicoy, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.115 · Cited by 108

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

van der Helm, L. H., Alhan, C., Wijermans, P., Kooy, M. V. M., Schaafsma, R., Biemond, B. J., Beeker, A., Hoogendoorn, M., van Rees, B. P., de Weerdt, O., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08893.x · Cited by 108

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification

Hasserjian, R. P., Zuo, Z., Garcia, C. A., Tang, G., Kasyan, A., Luthra, R., Abruzzo, L. V., Kantarjian, H. M., Medeiros, L. J., & Wang, S. A. (2009) · Blood · doi:10.1182/blood-2009-09-243964 · Cited by 108

Risk factors and their relationship to prognosis in myelodysplastic syndromes

Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00040-x · Cited by 19

Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories

Falantes, J. F., Calderón, C., Márquez-Malaver, F. J., Alonso, D., Noya, A. M., Carrillo, E., Martino, M. L., Montero, I., González, J., Parody, R., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.013 · Cited by 19

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688

Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes

Steidl, C., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kuendgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., et al. (2007) · Clinical Leukemia · doi:10.3816/clk.2007.n.029 · Cited by 8

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A. A. N., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 159